Arcellx merges with Gilead unit at $115 per share plus CVR
Arcellx agreed to merge with Gilead Sciences' cell therapy unit at $115 per share plus contingent value rights, valuing the combined entity at a significant premium to recent trading.
Arcellx agreed to merge with Gilead Sciences' cell therapy unit at $115 per share plus contingent value rights, valuing the combined entity at a significant premium to recent trading.
Elliott Management's push for PepsiCo operational improvements and portfolio optimization is now facing a test: the company must demonstrate credible margin expansion and growth acceleration or face renewed activist scrutiny.
CBRE Group completed a $750 million offering of senior unsecured notes due 2036 with a coupon of 5.250%, extending its debt maturity profile and refinancing existing obligations.
Medallion Financial completed a $75 million offering of senior secured notes due 2031 bearing an 8.25% coupon, strengthening liquidity and refinancing maturing debt.
Bradley Radoff and Jumana Capital have accumulated a 7.6% stake in Genesco and formed a group to pursue operational improvements and strategic alternatives at the footwear and apparel retailer.
The SEC issued an exemptive order reducing the minimum tender offer period for equity securities from 20 days to 10 days, accelerating corporate buyback and repurchase timelines across the market.
Lone Pine Capital disclosed significant portfolio repositioning in its most recent 13F filing, with moves across multiple sectors suggesting a shift in macro outlook or position conviction.